Evidence map›Paper›PMID 33832544›Full record

Trial reportEuropean journal of medical research2021

Echinacea reduces antibiotic usage in children through respiratory tract infection prevention: a randomized, blinded, controlled clinical trial.

Mercedes Ogal, Sebastian L Johnston, Peter Klein, Roland Schoop

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in European journal of medical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02971384 (Controlled, Randomized, Double-blind, Multicentre Study on Efficacy and Safety of Echinaforce Junior Tablets in Comparison With Vitamin C for the Prevention of Viral Respiratory Tract Infections in Children), which is not on this map. Cited by 25 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 3 pooled it
10.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02971384 phase3completednot on this map

Controlled, Randomized, Double-blind, Multicentre Study on Efficacy and Safety of Echinaforce Junior Tablets in Comparison With Vitamin C for the Prevention of Viral Respiratory Tract Infections in Children (4-12 Years)

TypeinterventionalSponsorA. Vogel AGRan2016 to 2018Enrolled203ConditionsRespiratory Tract Infection ViralArmsEchinaforce
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Vitamin C supplementation for prevention and treatment of pneumonia.The Cochrane database of systematic reviews · 2021
    Pooled it
  3. Vitamin C supplementation for prevention and treatment of pneumonia.The Cochrane database of systematic reviews · 2020
    Pooled it
  4. Adelmidrol to fight upper airways inflammation in children: a pilot case control study to safety and efficacy.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025
    Trial
  5. Review
  6. Review
  7. Pharmacological Insights and Technological Innovations inPharmaceuticals (Basel, Switzerland) · 2026
    Review
  8. Review
  9. Review
  10. The Use and Safety of Cough and Cold Medications in the Pediatric Population.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 3 countries.

Mercedes OgalPediatric Clinic, Brunnen, Switzerland.
Sebastian L JohnstonNational Heart and Lung Institute, Imperial College London, London, UK.
Peter Kleind.s.h. Statistical Services GmbH, Rohrbach, Germany.
Roland SchoopA Vogel AG, Grünaustrasse 4, 9325, Roggwil, TG, Switzerland. r.schoop@avogel.ch.ORCID http://orcid.org/0000-0002-0473-7697
Actelion (Switzerland) · CHImperial College London · GBKlinik Sonnenhof · CHStatistisches Bundesamt · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn children, up to 30% of viral respiratory tract infections (RTIs) develop into bacterial complications associated with pneumonia, sinusitis or otitis media to trigger a tremendous need for antibiotics. This study investigated the efficacy of Echinacea for the prevention of viral RTIs, for the prevention of secondary bacterial complications and for reducing rates of antibiotic prescriptions in children.

methodsEchinaforce® Junior tablets [400 mg freshly harvested Echinacea purpurea alcoholic extract] or vitamin C [50 mg] as control were given three times daily for prevention to children 4-12 years. Two × 2 months of prevention were separated by a 1-week treatment break. Parents assessed respiratory symptoms in children via e-diaries and collected nasopharyngeal secretions for screening of respiratory pathogens (Allplex® RT-PCR).

resultsOverall, 429 cold days occurred in N

conclusionsOur results support the use of Echinacea for the prevention of RTIs and reduction of associated antibiotic usage in children. Trial registration clinicaltrials.gov, NCT02971384, 23th Nov 2016.

Indexed as

Anti-Bacterial AgentsChildChild, PreschoolEchinaceaFemaleHumansMalePlant ExtractsRespiratory Tract InfectionsAnti-Bacterial AgentsPlant ExtractsAntibioticsAntiviralComplicationsEchinaceaPreventionRespiratory tract infections

Identifiers

PMID33832544
PMCPMC8028575
OpenAlexW3150792096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.